Alvotech (NASDAQ:ALVO) Sets New 52-Week Low After Analyst Downgrade

Alvotech (NASDAQ:ALVO)’s share price reached a new 52-week low during trading on Wednesday after UBS Group lowered their price target on the stock from $10.00 to $6.00. UBS Group currently has a buy rating on the stock. Alvotech traded as low as $3.03 and last traded at $3.13, with a volume of 1133730 shares trading hands. The stock had previously closed at $3.33.

A number of other brokerages also recently weighed in on ALVO. Zacks Research raised shares of Alvotech from a “strong sell” rating to a “hold” rating in a research note on Thursday, March 19th. Morgan Stanley set a $10.00 price target on Alvotech in a report on Wednesday, December 3rd. Barclays lowered their price objective on Alvotech from $5.00 to $4.00 and set an “underweight” rating for the company in a research report on Tuesday. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Alvotech in a research report on Wednesday, January 21st. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $7.60.

Trending Headlines about Alvotech

Here are the key news stories impacting Alvotech this week:

• Positive Sentiment: UBS reiterated a Buy on ALVO and cut its price target from $10 to $6, framing regulatory setbacks as largely priced in while pointing to underlying biosimilar strength that supports upside. Article Title
• Positive Sentiment: Coverage pieces highlight Alvotech’s ongoing execution in the biosimilar market and argue for continued growth potential, which could be supportive if revenue trends and margin progress continue. Alvotech Charts Course for Continued Growth in Biosimilar Market
• Positive Sentiment: Northland Securities published commentary on Alvotech’s FY2026 results (revenue beat but EPS miss in recent quarter), providing additional analyst attention that may help reprice the stock as investors parse forward guidance and pipeline milestones. Northland Securities Comments on Alvotech FY2026 Earnings
• Neutral Sentiment: Short-interest reports are inconsistent: one clean print shows a meaningful decline to ~2.46M shares short (≈0.8% of shares) as of March 13 with a short-interest ratio ~3.7 days — a modest short base. However, multiple March 23–24 data entries report “0 shares” (likely reporting glitches), so short-interest trends should be treated cautiously.
• Negative Sentiment: Barclays cut its price target from $5 to $4 and maintained an Underweight rating, a bearish signal that likely pressured the stock alongside broader downgrades. Article Title
• Negative Sentiment: Analyst target reductions overall (UBS lowered its PT despite keeping a Buy; Barclays trimmed target and kept Underweight) increase near-term uncertainty and likely contributed to the share decline as investors weigh regulatory risk, earnings misses, and execution against long-term biosimilar opportunity. Alvotech: Regulatory Setbacks Priced In…

Institutional Trading of Alvotech

A number of institutional investors have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. boosted its holdings in Alvotech by 40.9% in the 1st quarter. Goldman Sachs Group Inc. now owns 36,444 shares of the company’s stock valued at $352,000 after purchasing an additional 10,573 shares during the period. Geode Capital Management LLC raised its holdings in shares of Alvotech by 0.7% in the 2nd quarter. Geode Capital Management LLC now owns 230,291 shares of the company’s stock valued at $2,100,000 after acquiring an additional 1,574 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of Alvotech by 17.0% in the 2nd quarter. Legal & General Group Plc now owns 657,742 shares of the company’s stock valued at $6,028,000 after acquiring an additional 95,331 shares in the last quarter. Norges Bank bought a new stake in shares of Alvotech during the 2nd quarter valued at about $1,656,000. Finally, Invesco Ltd. boosted its position in shares of Alvotech by 37.3% during the 2nd quarter. Invesco Ltd. now owns 32,398 shares of the company’s stock valued at $295,000 after acquiring an additional 8,794 shares during the last quarter.

Alvotech Price Performance

The company has a fifty day moving average price of $4.46 and a 200 day moving average price of $5.77. The company has a market cap of $943.63 million, a PE ratio of 31.30 and a beta of 0.16.

Alvotech (NASDAQ:ALVO) last posted its quarterly earnings data on Wednesday, March 18th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.50). The firm had revenue of $173.20 million during the quarter, compared to analysts’ expectations of $162.20 million. Alvotech had a negative return on equity of 12.84% and a net margin of 4.74%. As a group, sell-side analysts predict that Alvotech will post -0.07 EPS for the current fiscal year.

Alvotech Company Profile

Alvotech (NASDAQ:ALVO) is a global biopharmaceutical company specializing in the development, manufacturing and commercialization of biosimilar medicines. The company focuses on creating high‐quality, cost‐effective alternatives to established biologic therapies in areas such as immunology, oncology and other specialty care fields. By leveraging in‐house research and a vertically integrated manufacturing platform, Alvotech aims to bring approved biosimilars to market more rapidly and with greater cost efficiency than many traditional biosimilar developers.

Since its founding in 2013, Alvotech has built a diversified pipeline of monoclonal antibody biosimilars, targeting blockbuster reference products including adalimumab (originally branded Humira), bevacizumab (Avastin) and ustekinumab (Stelara).